| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CAV2 |
| Uniprot No | P51636 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-162aa |
| 氨基酸序列 | MGLETEKADVQLFMDDDSYSHHSGLEYADPEKFADSDQDRDPHRLNSHLK LGFEDVIAEPVTTHSFDKVWICSHALFEISKYVMYKFLTVFLAIPLAFIA GILFATLSCLHIWILMPFVKTCLMVLPSVQTIWKSVTDVIIAPLCTSVGR CFSSVSLQLSQD |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CAV2重组蛋白的3篇模拟参考文献及摘要概括(注：文献信息为虚构示例，仅供参考)：
1. **《CAV2重组纤突蛋白在疫苗载体中的应用研究》**
作者：P. Ehrhardt, L. Holmgaard
摘要：本研究利用重组CAV2纤突蛋白构建新型疫苗载体，通过体外表达和纯化验证其稳定性，并在小鼠模型中证实其可有效递送抗原并诱导特异性免疫应答。
2. **《基于CAV2重组衣壳蛋白的基因递送系统优化》**
作者：S. Soudais, et al.
摘要：通过基因工程技术改造CAV2衣壳蛋白，增强其对神经元细胞的特异性靶向能力，实验证明重组蛋白介导的基因递送效率较野生型提高3倍，且细胞毒性降低。
3. **《CAV2重组蛋白与宿主受体相互作用的分子机制》**
作者：M. Cotugno, A. Aurisicchio
摘要：利用冷冻电镜和分子对接技术解析CAV2重组蛋白与宿主细胞受体CAR的结合位点，揭示其感染机制，为设计靶向性抗病毒药物提供结构基础。
4. **《CAV2重组E3蛋白在免疫逃逸中的功能分析》**
作者：J. Smith, R. González
摘要：通过敲除和回补实验证明CAV2重组E3蛋白可通过抑制干扰素通路帮助病毒逃逸宿主先天免疫，为开发减毒活疫苗提供理论依据。
(提示：实际研究中请通过PubMed、Google Scholar等平台检索真实文献。)
**Background of Recombinant CAV2 Protein**
Canine adenovirus type 2 (CAV2) is a non-enveloped, double-stranded DNA virus belonging to the *Adenoviridae* family. Unlike its close relative CAV1. which causes infectious canine hepatitis, CAV2 primarily induces mild respiratory infections in dogs. Its non-pathogenic nature in humans and efficient transduction capacity have made it a promising candidate for recombinant protein engineering and gene therapy applications.
The CAV2 genome is amenable to genetic modification, enabling the deletion of non-essential regions (e.g., E1 and E3) to create replication-defective vectors. These recombinant CAV2 vectors can carry large transgenes (up to ~30 kb) and efficiently deliver genetic material to both dividing and non-dividing cells. A key advantage of CAV2 is its tropism for specific cell types, including neurons and epithelial cells, mediated by its interaction with coxsackievirus-adenovirus receptors (CARs). This feature has driven its use in neuroscience research, particularly for retrograde neuronal circuit mapping and gene delivery to the central nervous system.
In vaccine development, recombinant CAV2 has been employed as a vector to express antigens from pathogens like rabies, parvovirus, or SARS-CoV-2. eliciting robust immune responses. Its low seroprevalence in humans reduces the risk of pre-existing immunity, enhancing therapeutic efficacy. Additionally, CAV2’s stability and scalability in production further support its utility in biomanufacturing.
Safety remains a priority; replication-deficient CAV2 vectors minimize unintended proliferation, making them suitable for clinical applications. Ongoing research explores their potential in treating genetic disorders, cancer, and neurodegenerative diseases. Overall, recombinant CAV2 represents a versatile, safe, and efficient platform for biomedical innovation.
×
